SeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome

Media coverage

• Title	SeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
  Media name/outlet	M2 Pharma
  Country/Territory	United States
  Date	29/09/23
  Persons	Kevin Chung

• Title	SeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
  Media name/outlet	FinancialWire
  Country/Territory	Australia
  Date	29/09/23
  Persons	Kevin Chung

• Title	SeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
  Media name/outlet	M2Pharma.com
  Country/Territory	United States
  Date	29/09/23
  URL	m2pharma.com/news/research-and-development/article.php?id=102098
  Persons	Kevin Chung

• Title	SeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
  Media name/outlet	M2 EquityBites
  Country/Territory	United Kingdom
  Date	29/09/23
  Persons	Kevin Chung